Prothena Q3 net loss narrows 55% to $16.51 million

• Prothena's third-quarter 2026 net loss narrowed 55% year-over-year to $16.51 million, while revenue fell 74% to $620,000.
• Research and development expenses dropped 71% year-over-year to $8.43 million due to lower clinical trial, personnel and consulting expenses.
• Partner-led Phase 3 trials of prasinezumab for Parkinson's disease and coramitug for ATTR-CM have primary completions expected in 2029.
• Full-year 2026 guidance remains $18 million–$23 million in operating and investing cash use, with approximately $259 million in year-end cash holdings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prothena Corporation plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20261105178540) on November 05, 2026, and is solely responsible for the information contained therein.